IL256000A - The quantification of the her 2 protein for optimal cancer treatment - Google Patents
The quantification of the her 2 protein for optimal cancer treatmentInfo
- Publication number
- IL256000A IL256000A IL256000A IL25600017A IL256000A IL 256000 A IL256000 A IL 256000A IL 256000 A IL256000 A IL 256000A IL 25600017 A IL25600017 A IL 25600017A IL 256000 A IL256000 A IL 256000A
- Authority
- IL
- Israel
- Prior art keywords
- quantification
- protein
- cancer treatment
- optimal cancer
- optimal
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168709P | 2015-05-29 | 2015-05-29 | |
| US201662310639P | 2016-03-18 | 2016-03-18 | |
| PCT/US2016/035118 WO2016196523A1 (en) | 2015-05-29 | 2016-05-31 | Quantifying her2 protein for optimal cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL256000A true IL256000A (en) | 2018-01-31 |
Family
ID=57397549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256000A IL256000A (en) | 2015-05-29 | 2017-11-28 | The quantification of the her 2 protein for optimal cancer treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10208130B2 (en) |
| EP (1) | EP3304072A4 (en) |
| JP (1) | JP6524266B2 (en) |
| KR (1) | KR102067327B1 (en) |
| CN (1) | CN108027360A (en) |
| AU (1) | AU2016270686B2 (en) |
| IL (1) | IL256000A (en) |
| WO (1) | WO2016196523A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3144394B1 (en) | 2010-12-08 | 2019-02-06 | Expression Pathology, Inc. | Truncated her2 srm/mrm assay |
| WO2017100663A1 (en) * | 2015-12-09 | 2017-06-15 | Expression Pathology, Inc. | Improved methods for treating her2-positive breast cancer |
| EP3630095A1 (en) * | 2017-06-02 | 2020-04-08 | Expression Pathology, Inc. | Predicting cancer treatment outcome with t-dm1 |
| US20220221460A1 (en) | 2019-03-08 | 2022-07-14 | Seoul National University R&Db Foundation | Method of quantifying her2 in breast cancer sample by mass spectrometry and scoring her2 status using the same |
| KR102462097B1 (en) * | 2020-12-30 | 2022-11-02 | 국립암센터 | Triple quadrupole-based multiple reaction monitoring for clinical therapeutic response prediction in cancer |
| CN115954046A (en) * | 2022-12-02 | 2023-04-11 | 上海爱谱蒂康生物科技有限公司 | Stomach cancer personalized treatment decision-making method and system and storage medium containing stomach cancer personalized treatment decision-making system |
| CN116819084A (en) * | 2023-03-16 | 2023-09-29 | 天津云检医学检验所有限公司 | Identification method and application of kit for identifying HER2 expression state of gastric cancer patient |
| CN116148482A (en) * | 2023-04-20 | 2023-05-23 | 天津云检医学检验所有限公司 | Device for identification of breast cancer patients and use for its preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
| JO3000B1 (en) * | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
| WO2008097229A1 (en) * | 2007-02-09 | 2008-08-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Method for spectroscopic quantitation of her-2 in biological samples |
| EP2585488A2 (en) * | 2010-06-24 | 2013-05-01 | Modpro AB | Novel biomarkers of liver cancer |
| EP3144394B1 (en) * | 2010-12-08 | 2019-02-06 | Expression Pathology, Inc. | Truncated her2 srm/mrm assay |
| JP2012237586A (en) * | 2011-05-10 | 2012-12-06 | Fujirebio Inc | Diagnostic reagent for selecting effective treatment method of anticancer agent |
| KR101992502B1 (en) * | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
| AU2012267888A1 (en) * | 2011-06-07 | 2014-01-30 | Caris Mpi, Inc. | Molecular profiling for cancer |
| ES3023516T3 (en) * | 2011-10-14 | 2025-06-02 | Hoffmann La Roche | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| CN104302286A (en) * | 2012-03-27 | 2015-01-21 | 英丘伦有限责任公司 | CURAXINS for use in treating breast cancer and method for identifying patients likely to respond |
-
2016
- 2016-05-31 JP JP2017561937A patent/JP6524266B2/en active Active
- 2016-05-31 EP EP16804267.9A patent/EP3304072A4/en not_active Withdrawn
- 2016-05-31 KR KR1020177037307A patent/KR102067327B1/en active Active
- 2016-05-31 US US15/169,724 patent/US10208130B2/en active Active
- 2016-05-31 AU AU2016270686A patent/AU2016270686B2/en active Active
- 2016-05-31 WO PCT/US2016/035118 patent/WO2016196523A1/en not_active Ceased
- 2016-05-31 CN CN201680044558.7A patent/CN108027360A/en active Pending
-
2017
- 2017-11-28 IL IL256000A patent/IL256000A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018517906A (en) | 2018-07-05 |
| JP6524266B2 (en) | 2019-06-05 |
| KR20180036653A (en) | 2018-04-09 |
| AU2016270686A1 (en) | 2018-01-25 |
| CN108027360A (en) | 2018-05-11 |
| US10208130B2 (en) | 2019-02-19 |
| EP3304072A4 (en) | 2018-12-05 |
| WO2016196523A1 (en) | 2016-12-08 |
| EP3304072A1 (en) | 2018-04-11 |
| AU2016270686B2 (en) | 2019-12-19 |
| US20160349259A1 (en) | 2016-12-01 |
| KR102067327B1 (en) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269026A (en) | Tumor treatment methods | |
| IL285151A (en) | Methods for the treatment of fgf21-related disorders | |
| IL258955A (en) | Preparations and methods for the treatment of cancer | |
| HUE064141T2 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL255261A0 (en) | Cancer treatment methods | |
| HUE059694T2 (en) | Preparation for the treatment of cancer | |
| PL3265053T3 (en) | WAYS OF TREATING THE SKIN | |
| IL263224A (en) | Methods and preparations for the treatment of cancer | |
| LT3283527T (en) | COMPREHENSIVE THERAPY FOR THE TREATMENT OF CANCER | |
| PL3600309T3 (en) | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF LIVER DISEASES | |
| PL3943093T3 (en) | APPLICATION OF PASTEURIZED AKKERMANSIA IN THE TREATMENT OF MALIGNANT CANCER | |
| HUE053191T2 (en) | 2-Heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL262211A (en) | Gene therapy for the treatment of type ii mucositis | |
| PL3197456T3 (en) | Cancer treatment | |
| IL256000A (en) | The quantification of the her 2 protein for optimal cancer treatment | |
| PT3458052T (en) | COMBINED TREATMENT OF CANCER | |
| IL256103B (en) | Compounds and methods for the treatment of celiac disease | |
| DK3576740T3 (en) | CANCER TREATMENT | |
| HUE053648T2 (en) | Therapeutic combinations for the treatment of cancer | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATED CANCER TREATMENT | |
| LT3377094T (en) | IMPAIRED VIRULARITY BACTERIA FOR THE TREATMENT OF MALICULAR SOLID TUMORS | |
| LT3534885T (en) | PHARNESYL TRANSANSERASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL308399A (en) | Cancer treatment methods | |
| IL281600A (en) | Cancer treatment methods |